These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2989319)

  • 1. Excess mineralocorticoid receptor activity in patients with dexamethasone-suppressible hyperaldosteronism is under adrenocorticotropin control.
    Speiser PW; Martin KO; Kao-Lo G; New MI
    J Clin Endocrinol Metab; 1985 Aug; 61(2):297-302. PubMed ID: 2989319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid and renal receptor binding activity of 21-deoxyaldosterone.
    Koshida H; Miyamori I; Soma R; Matsubara T; Ikeda M; Takeda R; Nakamura S; Kiuchi F; Tsuda Y
    Endocrinology; 1990 Mar; 126(3):1410-5. PubMed ID: 2155101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity.
    Krozowski ZS; Funder JW
    Proc Natl Acad Sci U S A; 1983 Oct; 80(19):6056-60. PubMed ID: 6310613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological evidence that the inhibition of diurnal adrenocorticotropin secretion by corticosteroids is mediated via type I corticosterone-preferring receptors.
    Dallman MF; Levin N; Cascio CS; Akana SF; Jacobson L; Kuhn RW
    Endocrinology; 1989 Jun; 124(6):2844-50. PubMed ID: 2542001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone receptors in different types of primary hyperaldosteronism.
    Armanini D; Witzgall H; Wehling M; Kuhnle U; Weber PC
    J Clin Endocrinol Metab; 1987 Jul; 65(1):101-4. PubMed ID: 3034947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexamethasone-suppressible hyperaldosteronism: a large new kindred.
    O'Mahony S; Burns A; Murnaghan DJ
    J Hum Hypertens; 1989 Aug; 3(4):255-8. PubMed ID: 2552113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexamethasone-suppressible hyperaldosteronism: pathophysiology, clinical aspects, and new insights into the pathogenesis.
    Fallo F; Sonino N; Boscaro M; Armanini D; Mantero F; Dörr HG; Knorr D; Kuhnle U
    Klin Wochenschr; 1987 May; 65(10):437-44. PubMed ID: 3037179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexamethasone-suppressible hyperaldosteronism. Adrenal transition cell hyperplasia?
    Connell JM; Kenyon CJ; Corrie JE; Fraser R; Watt R; Lever AF
    Hypertension; 1986 Aug; 8(8):669-76. PubMed ID: 3015796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RU-26988--a new tool for the study of the mineralocorticoid receptor.
    Gomez-Sanchez CE; Gomez-Sanchez EP
    Endocrinology; 1983 Sep; 113(3):1004-9. PubMed ID: 6307658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary dexamethasone-suppressible hyperaldosteronism and hyperprolactinemia].
    Veglio F; Pinna G; Rabbia F; Mulatero P; Chiandussi L
    Minerva Endocrinol; 1992; 17(1):43-6. PubMed ID: 1323053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal glomerulosa function in patients with dexamethasone-suppressible hyperaldosteronism.
    Oberfield SE; Levine LS; Stoner E; Chow D; Rauh W; Greig F; Lee SM; Lightner E; Witte M; New MI
    J Clin Endocrinol Metab; 1981 Jul; 53(1):158-64. PubMed ID: 7016891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term evolution of glucocorticoid-suppressible hyperaldosteronism.
    Stockigt JR; Scoggins BA
    J Clin Endocrinol Metab; 1987 Jan; 64(1):22-6. PubMed ID: 3536983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension corrected and aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible hyperaldosteronism.
    Woodland E; Tunny TJ; Hamlet SM; Gordon RD
    Clin Exp Pharmacol Physiol; 1985; 12(3):245-8. PubMed ID: 2992855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone suppressible hyperaldosteronism in a child with nephrosclerosis.
    Lee SM; Lightner E; Witte M; Oberfield S; Levine L; New MI
    Acta Endocrinol (Copenh); 1982 Feb; 99(2):251-5. PubMed ID: 6277130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid and metabolic response to metyrapone on normotensive children and children with dexamethasone-suppressible and primary hyperaldosteronism.
    Sonino N; Levine LS; New MI
    Acta Endocrinol (Copenh); 1981 Sep; 98(1):87-94. PubMed ID: 7025545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of aldosterone in the 7-day-old rat.
    Feuillan PP; Aguilera G
    Endocrinology; 1996 Sep; 137(9):3992-8. PubMed ID: 8756576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal receptor-binding activity of reduced metabolites of aldosterone: evidence for a mineralocorticoid effect outside of the classic aldosterone receptor system.
    Gomez-Sanchez CE; Smith JS; Ferris MW; Gomez-Sanchez EP
    Endocrinology; 1984 Aug; 115(2):712-5. PubMed ID: 6086276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum growth hormone levels measured by radioimmunoassay and radioreceptor assay: a useful diagnostic tool in children with growth disorders?
    Ilondo MM; Vanderschueren-Lodeweyckx M; De Meyts P; Eggermont E
    J Clin Endocrinol Metab; 1990 May; 70(5):1445-51. PubMed ID: 2186059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differing effects of metoclopramide and adrenocorticotropin on plasma aldosterone levels in glucocorticoid-suppressible hyperaldosteronism and other forms of hyperaldosteronism.
    Ganguly A; Pratt JH; Weinberger MH; Grim CE; Fineberg NS
    J Clin Endocrinol Metab; 1983 Aug; 57(2):388-92. PubMed ID: 6306041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the secretion of an antimineralocorticoid in congenital adrenal hyperplasia.
    Kuhnle U; Land M; Ulick S
    J Clin Endocrinol Metab; 1986 May; 62(5):934-40. PubMed ID: 3007560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.